Next Article in Journal
Effect of Cerebral Ischemia/Reperfusion Injury on Hydroxysafflor Yellow A Penetrating Across the Blood-Brain Barrier
Previous Article in Journal
Influence of Baicalin on Alveolar Bone Resorption in Rat Experimental Periodontitis
Article Menu

Article Versions

Export Article

Open AccessArticle
Sci. Pharm. 2008, 76(4), 699-712; doi:10.3797/scipharm.0809-05 (registering DOI)

Effect of Cilostazol in Alleviating Cardiovascular Complications through Regulation of Type 1 Plasminogen Activator Inhibitor and Transforming Growth Factor-β1 Overexpression in Experimental Rats

Department of Biochemistry, Faculty of Pharmacy, Zagazig University, Zip code 44511, Zagazig, Egypt
Received: 14 September 2008 / Accepted: 8 November 2008 / Published: 14 November 2008
Download PDF [282 KB, uploaded 28 December 2016]

Abstract

Cilostazol is a potent phosphodiesterase inhibitor; its major effects are prevention of platelet aggregation and dilation of blood vessels via an increase in tissue cAMP levels. This study examined the effect of cilostazol on serum cAMP, type 1 plasminogen activator inhibitor and transforming growth factor-β1 in relation to alleviating cardiovascular complications. This was achieved in rats through administration of L-NAME (0.1 mg/ml) for two weeks, and then followed by i.p. single dose of streptozotocin (65mg/kg). Rats were classified to three groups; normal rats, control diabetic hypertensive rats and the third group was treated with cilostazol (1.8 mg daily, orally) for six weeks. Cilostazol improved serum cAMP level and increased plasma NO concentration leading to dilation of blood vessels. In addition, cilostazol has beneficial lipoprotein-modifying effect. Cilostazol treatment confirmed the positive correlation between plasma PAI-1 activity and serum TGF-β1 which is beneficial in reducing the hazards of cardiovascular complications. Thus, cilostazol therapy provides a broad spectrum of effects in alleviating cardiovascular complications induced in experimental animals.
Keywords: Cilostazol phosphodiesterase inhibitor; Cyclic AMP; Plasminogen activator inhibitor-1; Transforming growth factor-β1; Cardiovascular complications Cilostazol phosphodiesterase inhibitor; Cyclic AMP; Plasminogen activator inhibitor-1; Transforming growth factor-β1; Cardiovascular complications
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

MOHAMED, R.H. Effect of Cilostazol in Alleviating Cardiovascular Complications through Regulation of Type 1 Plasminogen Activator Inhibitor and Transforming Growth Factor-β1 Overexpression in Experimental Rats. Sci. Pharm. 2008, 76, 699-712.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Sci. Pharm. EISSN 2218-0532 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top